MAN VAN

  • Research type

    Research Study

  • Full title

    The Man Van Project: An evaluation of the effectiveness of a mobile outreach screening clinic model for earlier detection of prostate cancer and other male cancers.

  • IRAS ID

    304320

  • Contact name

    Nicholas James

  • Contact email

    nick.james@icr.ac.uk

  • Sponsor organisation

    The Royal Marsden NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 2 months, 28 days

  • Research summary

    Prostate cancer is the most common cancer in men, with around 52,300 new cases diagnosed every year. Research has shown that early diagnosis has a direct link to surviving the disease, with 100% of men diagnosed at the earliest stage of prostate cancer surviving for 5 years of more. When prostate cancer is diagnosed at its’ latest stage, only ½ (49%) of all men will survive for 5 years or more.

    Currently, prostate cancer is initially suspected through a check carried out by a GP and men are referred into a Hospital for further tests and imaging to confirm a diagnosis. Research also shows that many men do not know the signs and symptoms of early prostate cancer and also have a feeling of embarrassment about being screened for the disease, even if they do not have symptoms. This means that many men present with the disease late and their treatment options are limited, increasing the risk of death from the disease.

    The Royal Marsden NHS Foundation Trust set-up the Man Van mobile outreach clinic in 2021. This new NHS service brings the Hospital clinical care team into the community, by targeting medium to large sized employers. The Man Van clinic aims to screen 10,500 men over the next 3 years for prostate and other male cancers as well as other diseases such as heart disease and Type II diabetes.

    The routine clinical data collected from the first cohort of men (n=300) who use the Man Van clinic in its' first few months of operation, will be analysed to see how effective a mobile outreach clinic is in identifying prostate cancer earlier as well as other male cancers and other diseases.

  • REC name

    Wales REC 6

  • REC reference

    22/WA/0113

  • Date of REC Opinion

    13 Apr 2022

  • REC opinion

    Favourable Opinion